Outcome from the End-of-Phase 1 Meeting with the FDA and Pivotal Ph 2 Trial Design for OMNI-EGFR™ Inhibitor, BH-30643, in EGFR C797S-Positive NSCLC Announced November 11, 2026
Astellas and Audax Biosciences Enter Exclusive Option and License Agreement for DAX-044 for Immuno-Oncology November 11, 2026
Updated Clinical Data of Zocilurtatug Pelitecan (Zoci) in Previously Treated Extrapulmonary Neuroendocrine Carcinomas Presented November 11, 2026
Helix 51 Company Saros Therapeutics Receives Second $2 Million Award to Advance Cancer Immunotherapy November 11, 2026
First Patient Dosed in OVACT Ph 1/1b Trial of CryptiVax™-1001 in Advanced High-Grade Serous Ovarian Cancer November 11, 2026
Preliminary Findings from the Investigator-Sponsored Ph 2a PICASSO Trial in Metastatic Melanoma Announced November 11, 2026
Boehringer Ingelheim and SBP Group enter partnership to advance next-generation cancer therapies November 11, 2026
Zenith Epigenetics and Lilly to collaborate on Registration Enabling Study of ZEN-3694 and Verzenio® (Abemaciclib) in NUT Carcinoma November 11, 2026
T-Therapeutics announces oversubscribed $133 million Series B financing to achieve clinical proof-of-concept for first-in-class TCR bispecific therapies in cancer and autoimmune disease November 11, 2026
Ph 1/2 Study of Vopimetostat in Combination with ERAS-0015 Initiated in patients with MTAP-deleted pancreatic cancer and MTAP-deleted/RAS mutant NSCLC November 11, 2026
Incremental Data and Analyses from Ph 1/2a Trial of [212Pb]Bamzireotide Navoxetan (VMT-α-NET) in Advanced SSTR2 Expressing NETs Presented November 11, 2026
Ph 2a PICASSO Trial of MaaT013 (Xervyteg®) + immune checkpoint inhibitors in selected melanoma patients met primary endpoint November 11, 2026
Positive QoL Data for LYMPHIR® (denileukin diftitox-cxdl) in R/R Cutaneous T-Cell Lymphoma Presented November 11, 2026
Ph 2 Study of Ivonescimab in the Perioperative Setting for Resectable NSCLC Published in Nature Medicine November 11, 2026
Regulatory Filings Accepted for Review for ORPATHYS® plus TAGRISSO® in MET-Driven EGFR-Mutated Lung Cancer in Europe and Japan November 11, 2026
Lirafugratinib (Lyrfigtu) Added to NCCN Guidelines as 2L Therapy for Cholangiocarcinoma with FGFR2 Fusion or Other Rearrangement November 11, 2026
FDA PDUFA Date for Resubmitted NDA for Rivoceranib + Camrelizumab combo in 1L Unresectable or Metastatic HCC Announced November 11, 2026
